Jump to content
SCLERO.ORG
Sclero Forums

Search the Community

Showing results for tags 'clinical trials'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 20 results

  1. Would you like to help scientists find a cure for scleroderma? Dozens of clinical trials for scleroderma and pulmonary hypertension are actively recruiting now. Review them and be sure to ask your scleroderma expert about the ones you are interested in. Posted 12/09/2014. (Also see: Current Clinical Trials and Scleroderma Experts) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Lenabasum Fails to Show Efficacy in Diffuse Cutaneous Scleroderma (dcSSc), Phase 3 Trial Shows. Treatment with lenabasum failed to outperform a placebo when given as an add-on to standard immunosuppressants in adults with dcSSc, top-line data from a Phase 3 trial show. Scleroderma News, 09/09/2020. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say. The ongoing COVID-19 pandemic has begun to cause delays in the development of gene therapies to treat a variety of rare diseases. Scleroderma News, 05/28/2020. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Case Report: COVID-19 in a patient with systemic sclerosis (SSc) treated with tocilizumab for Ssc-interstitial lung disease (ILD.) Our case indicates that IL-6-blocking treatment given for chronic autoimmune diseases may even prevent the development of severe COVID-19. BMJ Journals, Ann rheumatologist Dis. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the forced vital capacity was significantly lower among patients who received nintedanib than among those who received placebo. PubMed, N Engl J Med, 2019 Oct 31;381(18):1718-1727. (Also see Clinical Trials and Treatments for Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus. We show that Belimumab-mediated B-cell activating factor depletion reduces the Transitional 2 subset in patients. PubMed, Lupus, 2019 Oct;28(11):1337-1343. (Also see Treatments for Lupus and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Phase 2 Study of Bermekimab in Treating Scleroderma Enrolls 1st Patient. The first person has been enrolled in a clinical trial evaluating the investigational therapy bermekimab in adults with scleroderma, XBiotech, the developer of bermekimab, announced. Scleroderma News, 10/07/2019. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers (SSc-DU). In participants with SSc-DU, treatment with riociguat did not reduce the number of DU net burden compared with placebo at 16 weeks. PubMed, Arthritis Res Ther, 2019 Sep 3;21(1):202. (Also see Treatments for Digital Ulcers and Clinical Trials: Completed, Negative Results) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Tocilizumab and the Risk of Cardiovascular Disease (CVD): Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis (RA) Patients. Tocilizumab was associated with a CVD risk comparable to that for etanercept as well as a number of other biologics used for the treatment of RA. PubMed, Arthritis Care Res (Hoboken), 2019 Aug;71(8):1004-1018. (Also see Treatments for Rheumatoid Arthritis and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. FDA approves first treatment for patients with rare type of lung disease. The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. FDA News Release, 09/06/2019. (Also see Treatments for Pulmonary Fibrosis and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated interstitial lung disease (ILD). Results show that nintedanib slows the loss of pulmonary function in patients with SSc-ILD compared to placebo. Business Wire, 05/20/2019. (Also see Clinical Trials and Treatments for Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Effects of treatment with rituximab on microcirculation in patients with long–term systemic sclerosis. Rituximab improves microcirculation in long–term SSc and stabilization and reduced progression of microcirculation abnormalities were achieved. PubMed, BMC Res Notes, 2018 Dec 10;11(1):874. (Also see Biologic Agents and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Phase 2a Trial Will Evaluate GLPG1690 in Diffuse Cutaneous Scleroderma. A Phase 2a clinical trial will test the investigational therapy GLPG1690 in patients with diffuse cutaneous scleroderma. Scleroderma News, 01/10/2019. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. FDA Grants Fast Track Status to Fibrocell's Gene Therapy FCX-013 for Localized Scleroderma. Fibrocell Science's gene therapy candidate FCX-013 received fast track designation by the U.S. Food and Drug Administration as a treatment for moderate––to–severe localized scleroderma. Scleroderma News, 09/06/2018. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  15. Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis. Corbus Pharmaceuticals announced today that the Company will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis. Globe Newswire, 07/25/2018. (Also see Treatments for Dermatomyositis, Endocannabinoid System and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  16. Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast. This was a small single center study and the role of tranilast in the management in scleroderma warrants further investigation in larger trials. Dove Press, 07/04/2018. (Also see Clinical Trials and Morphea Treatments) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  17. Should all digital ulcers (DUs) be included in future clinical trials of systemic sclerosis (SSc)–related digital vasculopathy? We would encourage the expert SSc community to reconsider the rationale for including only fingertip DUs in future SSc clinical trials, and suggest an agenda for future research. PubMed, Med Hypotheses, 2018 Jul;116:101-104. (Also see Research on Digital Ulcers) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  18. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis (SSc). The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases. PubMed, Ann rheumatologist Dis, 05/31/2018. (Also see Interleukins and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  19. Lenabasum Safe and Effective in Diffuse Scleroderma Patients, One–year Trial Data Show. Lenabasum, by Corbus Pharmaceuticals, was shown to be safe, well-tolerated and of benefit to patients treated for one year in a long-term extension of a Phase 2 trial. Scleroderma News, 05/17/2018. (Also see Clinical Trials and Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  20. iBio Selects Lead Candidate for its Fibrosis Therapeutics Program. iBio, Inc. announced today that it had selected an E4-Fc fusion protein as its lead candidate for further development of a drug against fibrotic diseases, including systemic sclerosis and idiopathic pulmonary fibrosis. Globe Newswire, 03/14/2018. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...